top of page

Allergan acquires Motus following positive diabetic gastroparesis trial

Results of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Motus’ ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes has led to Allergan exercising its option to acquire Motus Therapeutics.

READ MORE

source:http://www.europeanpharmaceuticalreview.com/45086/news/industry-news/allergan-motus-gastroparesis/

#Pharmanews

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page